These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 35484662)

  • 1. Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis.
    Arribas AJ; Napoli S; Cascione L; Sartori G; Barnabei L; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; Castro de Moura M; Jovic S; Bordone-Pittau R; Di Veroli A; Stathis A; Cruciani G; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
    Haematologica; 2022 Nov; 107(11):2685-2697. PubMed ID: 35484662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms.
    Arribas AJ; Napoli S; Cascione L; Barnabei L; Sartori G; Cannas E; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; de Moura MC; Jovic S; Pittau RB; Stathis A; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
    bioRxiv; 2023 Jan; ():. PubMed ID: 36711490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ERBB4-Mediated Signaling Is a Mediator of Resistance to PI3K and BTK Inhibitors in B-cell Lymphoid Neoplasms.
    Arribas AJ; Napoli S; Cascione L; Barnabei L; Sartori G; Cannas E; Gaudio E; Tarantelli C; Mensah AA; Spriano F; Zucchetto A; Rossi FM; Rinaldi A; Castro de Moura M; Jovic S; Bordone Pittau R; Stathis A; Stussi G; Gattei V; Brown JR; Esteller M; Zucca E; Rossi D; Bertoni F
    Mol Cancer Ther; 2024 Mar; 23(3):368-380. PubMed ID: 38052765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic and toxicological considerations for phosphoinositide 3-kinase delta inhibitors in the treatment of chronic lymphocytic leukemia.
    Witkowska M; Majchrzak A; Robak P; Wolska-Washer A; Robak T
    Expert Opin Drug Metab Toxicol; 2023 Sep; 19(9):617-633. PubMed ID: 37714711
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-6 mediates resistance to PI3K-pathway-targeted therapy in lymphoma.
    Kim JH; Kim WS; Park C
    BMC Cancer; 2019 Oct; 19(1):936. PubMed ID: 31601188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
    Davids MS; O'Connor OA; Jurczak W; Samaniego F; Fenske TS; Zinzani PL; Patel MR; Ghosh N; Cheson BD; Derenzini E; Brander DM; Reeves JA; Knopińska-Posłuszny W; Allan JN; Phillips T; Caimi PF; Lech-Maranda E; Burke JM; Agajanian R; Pettengell R; Leslie LA; Cheah CY; Fonseca G; Essell J; Chavez JC; Pagel JM; Sharman JP; Hsu Y; Miskin HP; Sportelli P; Weiss MS; Flinn IW
    Blood Adv; 2021 Dec; 5(23):5332-5343. PubMed ID: 34547767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.
    Lampson BL; Brown JR
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1267-1279. PubMed ID: 28945111
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond.
    Lue JK; O'Connor OA; Bertoni F
    Ann Lymphoma; 2020 Sep; 4():7. PubMed ID: 34667996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
    Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
    Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies.
    Cooney JD; Lin AP; Jiang D; Wang L; Suhasini AN; Myers J; Qiu Z; Wölfler A; Sill H; Aguiar RCT
    Clin Cancer Res; 2018 Mar; 24(5):1103-1113. PubMed ID: 29246942
    [No Abstract]   [Full Text] [Related]  

  • 11. Marginal Zone Lymphoma: State-of-the-Art Treatment.
    Sindel A; Al-Juhaishi T; Yazbeck V
    Curr Treat Options Oncol; 2019 Dec; 20(12):90. PubMed ID: 31807935
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies.
    Roskoski R
    Pharmacol Res; 2021 Jun; 168():105579. PubMed ID: 33774181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib.
    Proudman D; Nellesen D; Gupta D; Adib D; Yang J; Mamlouk K
    Adv Ther; 2022 Apr; 39(4):1678-1696. PubMed ID: 35157216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.
    Yang Q; Modi P; Newcomb T; Quéva C; Gandhi V
    Clin Cancer Res; 2015 Apr; 21(7):1537-42. PubMed ID: 25670221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI3Kδ inhibitor idelalisib in combination with BTK inhibitor ONO/GS-4059 in diffuse large B cell lymphoma with acquired resistance to PI3Kδ and BTK inhibitors.
    Yahiaoui A; Meadows SA; Sorensen RA; Cui ZH; Keegan KS; Brockett R; Chen G; Quéva C; Li L; Tannheimer SL
    PLoS One; 2017; 12(2):e0171221. PubMed ID: 28178345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond.
    Wei M; Wang X; Song Z; Jiao M; Ding J; Meng LH; Zhang A
    Med Res Rev; 2015 Jul; 35(4):720-52. PubMed ID: 25763934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells.
    Maharaj K; Powers JJ; Achille A; Mediavilla-Varela M; Gamal W; Burger KL; Fonseca R; Jiang K; Miskin HP; Maryanski D; Monastyrskyi A; Duckett DR; Roush WR; Cleveland JL; Sahakian E; Pinilla-Ibarz J
    Blood Adv; 2020 Jul; 4(13):3072-3084. PubMed ID: 32634240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Umbralisib: First Approval.
    Dhillon S; Keam SJ
    Drugs; 2021 May; 81(7):857-866. PubMed ID: 33797740
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective management strategies for patients with marginal zone lymphoma.
    Rosand CB; Valla K; Flowers CR; Koff JL
    Future Oncol; 2018 May; 14(12):1213-1222. PubMed ID: 29260925
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II study of the PI3K inhibitor copanlisib in combination with the anti-CD20 monoclonal antibody rituximab for patients with marginal zone lymphoma: treatment rationale and protocol design of the COUP-1 trial.
    Grunenberg A; Kaiser LM; Woelfle S; Schmelzle B; Viardot A; Möller P; Barth TFE; Muche R; Dreyhaupt J; Raderer M; Kiesewetter B; Buske C
    BMC Cancer; 2021 Jun; 21(1):749. PubMed ID: 34187401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.